Larvol Delta - A-proofofconcept-study-evaluating-AB102-as-a-potential-oral-therapy-for-patients-with-chronic-spontaneous-urticaria-is-expected-in-mid2027

AB102 - Arcus Biosciences

https://www.businesswire.com/news/home/20260805395862/en/Arcus-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-a-Pipeline-Update

Aug 5, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next